XML 16 R4.htm IDEA: XBRL DOCUMENT v3.25.1
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) - USD ($)
shares in Thousands
 3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Income Statement [Abstract]    
Revenue [1] $ 483,649,000 $ 639,653,000
Expenses    
Cost of revenue [1] 381,178,000 535,547,000
Selling, general and administrative expenses [1] 78,409,000 79,104,000
Depreciation and amortization expenses 24,058,000 29,503,000
Loss on lease termination 1,906,000 0
Change in fair value of contingent consideration (280,000) 8,908,000
Total operating expenses 485,271,000 653,062,000
Operating loss (1,622,000) (13,409,000)
Interest income 1,274,000 2,550,000
Interest expense (10,385,000) (5,997,000)
Gain (loss) from equity method investees (19,000.0) 306,000
Gain (loss) on option exercise (52,348,000) 0
Change in tax receivables agreement liability 0 (173,000)
Other income (expense), net (48,000) 8,000
Loss before income taxes (63,148,000) (16,715,000)
Provision for income taxes 1,470,000 565,000
Loss before preferred dividends and accretion of Series A Preferred Stock (64,618,000) (17,280,000)
Dividends and accretion of Series A Preferred Stock (7,632,000) (7,945,000)
Net loss attributable to common shareholders of Evolent Health, Inc. - basic (72,250,000) (25,225,000)
Net loss attributable to common shareholders of Evolent Health, Inc. - diluted $ (72,250,000) $ (25,225,000)
Loss per common share    
Basic (in dollars per share) $ (0.63) $ (0.22)
Diluted (in dollars per share) $ (0.63) $ (0.22)
Weighted-average common shares outstanding    
Basic (in shares) 115,315 114,141
Diluted (in shares) 115,315 114,141
Comprehensive loss    
Net loss attributable to common shareholders of Evolent Health, Inc. $ (72,250,000) $ (25,225,000)
Other comprehensive loss, net of taxes, related to:    
Foreign currency translation adjustment 24,000 (51,000)
Total comprehensive loss attributable to common shareholders of Evolent Health, Inc. $ (72,226,000) $ (25,276,000)
[1] See Note 18 for amounts attributable to unconsolidated related parties included in these line items.